This paper was published through Galoá and has a deposited DOI. To cite this paper, use one of the standards below:
In case you are one of the co-authors and want to register this paper in your Lattes, use the following code: doi > 10.17648/htbr-2021-125112
If you've NEVER registered a DOI in your Lattes, check our tutorial!Please log in to watch the video
Log inINTRODUCTION: In 2018, colorectal cancer (CRC) was the fourth most incident cancer worldwide (10.2%) and the third leading cause of cancer death (9.2%). Its early diagnosis allows the institution of treatment in earlier stages of cancer, promoting a reduction in its morbidity and mortality. This study aims to evaluate the effectiveness of population screening for CCR by fecal occult blood tests in adults aged from 45 to 75 years. METHODS: The outcomes were overall mortality and CRC mortality. Search strategies were applied to MEDLINE, EMBASE, LILACS and CENTRAL. Five reviewers independently selected the studies. For each selected clinical trial, the risk of bias was assessed according to the criteria described in the Cochrane Manual for Systematic Reviews of Interventions. Reviewers used a specific data extraction form to record information from the selected studies. The relative risk (RR) was calculated with a 95% confidence interval (CI) as an estimate of the intervention’s effect. Similar outcomes were plotted in the meta-analysis and a random-effect model was used for the meta-analysis. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to evaluate the certainty of evidence. RESULTS: Twelve randomized controlled trials (RCTs) were included, in which asymptomatic individuals – with standard risk for CRC – underwent guaiac fecal occult blood test (gFOBT), while the control group was not screened. In total, 337.377 individuals were screened with gFOBT and biennial frequency (intervention group), while 337.192 individuals did not participate in the screening (control group). In relation to mortality due to CRC, a reduction of 12% was verified (RR: 0.88, 95% CI, 0.84 to 0.92, twelve studies, 674.569 participants, moderate quality of evidence) in the intervention group compared to the control group. We found no significant difference in the overall mortality (RR 1.00, 95% CI, 1.00 to 1.01, moderate quality of evidence). CONCLUSION: Population screening for CRC in individuals aged from 45 to 75 years was able to reduce mortality from this cancer by 12% and had no effect on overall mortality.
Funding: São Paulo State Research Support Foundation (FAPESP). Process number: 2019/19386-2
PROSPERO (registration number: CRD42020169541)
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper